We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
17
Jul 2026
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - a type of medication that mimics the GLP-1 hormone - to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.
17
Jul 2026
Researchers at Japan's National Institutes for Quantum Science and Technology (QST) have found that tau buildup in progressive supranuclear palsy (PSP) may affect brain networks involved in thinking and behavior.
17
Jul 2026
Brain tumor surgeries are particularly challenging due to the difficult trade-off neurosurgeons often face—remove more tumor and risk neurological injury, or preserve function and leave more tumor behind.
17
Jul 2026
Nearly 90 years after Ugo Cerletti and Lucio Bini introduced electroconvulsive therapy (ECT), brain stimulation therapies such as ECT and Repetitive Transcranial Magnetic Stimulation (rTMS) are common in psychiatry because they are highly effective for treating depression and schizophrenia, yet their cellular mechanisms remain poorly understood